Prospective drug utilization evaluation of three broad-spectrum antimicrobials: Cefepime, piperacillin-tazobactam and meropenem

QJM: An International Journal of Medicine

Volumn 99, Issue 6, 2006, Pages 397-406

  Raveh, D ^a   Muallem Zilcha, E ^a,c   Greenberg, A ^a,b   Wiener Well, Y ^a   Schlesinger, Y ^a   Yinnon, A M ^a,d  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFEPIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BACTERIUM CULTURE; DRUG CHOICE; DRUG COST; DRUG USE; DRUG UTILIZATION; EMPIRICISM; HUMAN; INFECTION; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS;

EID: 33745595038     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl050     Document Type: Article

References (35)

1. Kollef M, Niederman M. Antimicrobial resistance in the ICU: The time for action is now. Crit Care Med 2001; 29(4 suppl.):N63.
2. Jarvis W. Preventing the emergence of multidrug resistant microorganisms through antimicrobial use controls: The complexity of the problem. Infect Contr Hosp Epidemiol 1996; 17:490-5.
3. Kunin CM. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 1993; 118:557-61.
4. Marcus EL, Clarfield AM, Moses AE. Ethical issues relating to the use of antimicrobial therapy in older adults. Clin Infect Dis 2001; 33:1697-703.
5. Roark MK, Reed WE Jr. Econotherapeutics. Diagn Microbiol Infect Dis 1995; 22:209-17.
6. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in Antimicrobial Agent Usage Resulting from Interactions Among Clinical Pharmacy, the Infectious Disease Division, and the Microbiology Laboratory. Diagn Microbiol Infect Dis 1993; 16:255-64.
7. Ibrahim KH, Gunderson B, Rotschafer JC. Intensive care unit antimicrobial resistance and the role of the phramacist. Crit Care Med 2001; 29(4 suppl.):N108-13.
8. Yinnon AM, Skorohod Y, Schlesinger Y, Greenberg A. Cefuroxime utilization evaluation: Impact of physician education on prescribing patterns. Isr Med Assoc J 2000; 2:187-91.
9. Hammerman A, Greenberg A, Yinnon AM. Drug use evaluation of ciprofloxacin: Impact of educational efforts on appropriateness of use. J Clin Pharm Ther 1997; 22:415-20.
10. Kane RL, Garrard J. Changing physician prescribing practices: Regulation vs education. JAMA 1994; 271:393-4.
11. Masterton RG. Antibiotic policies and the role of strategic hospital leadership. J Hosp Infect 1999; 43(Suppl.):S261-4.
12. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996; 275:234-40.
13. Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: A statement by the Infectious Disease Society of America. J Infect Dis 1988; 157:869-76.
14. Rifenburg RP, Paladino JA, Hanson SC, Tuttle JA, Schentag JJ. Benchmark analysis of strategies hospital use to control antimicrobial expenditures. Am J Health Sys Pharm 1996; 53:2054-62.
15. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes. Ann Intern Med 1996; 124:884-90.
16. English S, Scott E. Empiric therapy for treatment of infection and the influence of antibiotic guidelines on outcomes. Int J Pharm Practice 1995; 3:231-5.
17. Belognia EA, Schwartz B. Strategies for promoting judicious use of antibiotics by doctors and patients. Br Med J 1998; 317:668-671.
18. ASHP guidelines on the pharmacist's role in drug-use evaluation. Am J Hosp Pharm 1988; 45:385-6.
19. Yinnon AM, Schlesinger Y, Jersassy Z, Raveh D, eds. Recommendations for antimicrobial usage in common clinical conditions. Jerusalem, Pocketbook (Hebrew). Almog Ltd, 2004.
20. Moellering RC Jr., Eliopoulos GM. Principles of anti-infective therapy. In: Mandell GL, Bennett JE, Dolin R, eds. Principles, & Practice of Infectious Diseases. 6th edn. Philadelphia, USA, Churchill Livingstone, 2005:242-53.
21. Chambers HF, Hadley KW, Jawetz E. Chemotherapeutic Drugs. In: Katzung BG, ed. Basic and Clinical Pharmacology. 7th edn. Connecticut, Appleton & Lange, 1998:724-87.
22. Marra F, Reynolds R, Stiver G, et al. Tazobactam versus imipenem: A double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998; 31:355-68.
23. Hurst M, Lamb HM. Meropenem: A review of its use in patients in intensive care. Drugs 2000; 59:653-80.
24. Beaucaire G. Clinical activity of cefepime in severe infections. Clin Microbiol Infect 1999;5(Suppl. 1):S6-14.
25. Raveh D, Rudensky B, Schlesinger Y, Benenson S, Yinnon AM. Susceptibility trends in bacteraemias: Analyses of 7544 patient-unique bacteraemic episodes spanning 11 years (1990-2000). J Hosp Infect 2003; 55:196-203.
26. Raveh D, Rudensky B, Huerta M, Aviv Y, Yinnon AM. Use of time-trend analysis in the design of empirical antimicrobial treatment of urinary tract infection. Eur J Clin Microbiol Infect Dis 2003; 22:158-64.
27. Tallis E, Rudensky B, Attias D, Raveh D, Schlesinger Y, Yinon AM. In vitro activity of cefepime and other broad spectrum antimicrobials against several groups of Gram-negative bacilli and Staphylococcus aureus. Diagn Microbiol Infect Dis 1999; 35:121-6.
28. Cars O, Molstad S, Melander A. Variation in antibioitc use in the European Union. Lancet 2001; 357:1851-3.
29. Raveh D, Levy Y, Schlesinger Y, Greenberg A, Rudensky B, Yinnon AM. Longitudinal surveillance of antibiotic use in the hospital. Q J Med 2001; 94:141-52.
30. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial resistant bacteria in hospitals. Infect Dis Clin North Am 1997; 11:757-65.
31. Drori-Zeides T, Raveh D, Schlesinger Y, Yinnon AM. Practical guidelines for vancomycin usage, with prospective drug utilization evaluation. Infect Control Hosp Epidemiol 2000; 21:45-7.
32. Bailey TC, Troy McMullin S. Using information systems technology to improve antibiotic prescribing. Crit Care Med 2001; 29(4 Suppl.):N87-91.
33. Yinnon AM. Whither infectious diseases consultations. Analysis of 14,005 consultations from a 5-year period. Clin Infect Dis 2001; 33:1661-7.
34. Thuong M, Shorthen F, Zazempa V, Girou E, Soussy CJ, Brun-Buisson C. Appropriate use of restricted antimicrobial agents in hospitals: The importance of empirical therapy and assisted evaluation. J Antimicrob Chemother 2000; 46:501-8.
35. Raveh D, Gratch L, Yinnon AM, Sonnenblick M. Epidemiological and clinical characteristics of patients admitted to medical and geriatric departments. A prospective, comparative and observational study. J Eval Clin Pract 2005; 11:33-44.